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Résumé en
anglais
RNA interference currently offers new opportunities for gene therapy by the
specific extinction of targeted gene(s) in cancer diseases. However, the main
challenge for nucleic acid delivery still remains its efficacy through intravenous
administration. Over the last decade, many delivery systems have been developed
and optimized to encapsulate siRNA and to specifically promote their delivery into
tumor cells and improve their pharmacokinetics for anti-cancer purposes. This
review aims to sum up the potential targets in numerous pathways and the
properties of recently optimized siRNA synthetic nanomedicines with their
preclinical applications and efficacy. Future perspectives in cancer treatment are
discussed including promising concomitant treatment with chemotherapies or
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